Eg5 Motor Inhibitors Mitigate Microtubule Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-cancer therapies targeting microtubule dynamics face toxicity issues due to the essential role of microtubules in cellular functions, limiting their use, and existing Eg5 inhibitors have limitations in specificity and effectiveness, particularly for non-mammalian models and clinical applications.
Innovation Solution
Development of compounds that inhibit the Eg5 motor protein, specifically designed to target the allosteric sites of Eg5, disrupting its ATPase activity and interfering with mitotic spindle formation, thereby inducing apoptosis in cancer cells with minimal impact on interphase microtubule dynamics, and formulation of these compounds into pharmaceutical compositions for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If microtubule disrupters are used as chemotherapeutics, then cell division is interfered with resulting in cell death, but toxicity issues arise due to the essential role of microtubules in many cellular functions
Solution Approach 1:
The invention segments the anti-cancer therapeutic approach by targeting a specific component (Eg5 motor protein) rather than the entire microtubule system. This allows selective inhibition of mitotic function while preserving other microtubule-dependent cellular processes, thereby reducing toxicity while maintaining anti-cancer effectiveness
Solution Approach 2:
The compounds exhibit local quality by demonstrating selective activity - they specifically inhibit Eg5 motor protein function during mitosis while having minimal impact on other cellular functions. This localized effect at the Eg5 protein level achieves cancer cell killing without the broad toxicity associated with general microtubule disrupters
2Reliability
If existing Eg5 inhibitors are used, then Eg5 ATPase activity is inhibited, but limitations in specificity and effectiveness remain particularly for non-mammalian models and clinical applications
Solution Approach 1:
The compounds are designed with universal applicability across different species and model systems. The chemical structure allows them to bind to the conserved allosteric site of Eg5 in both mammalian and non-mammalian organisms, making them versatile tools for research and potential clinical applications while maintaining high effectiveness
Solution Approach 2:
The invention optimizes molecular parameters of the inhibitor compounds to enhance both binding affinity and selectivity. By adjusting structural parameters and chemical properties, the compounds achieve improved effectiveness against Eg5 while maintaining specificity, enabling their use across diverse experimental and clinical contexts
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Eg5 inhibitors effectively arrest cancer cells in mitosis, leading to apoptosis with reduced toxicity and improved specificity, demonstrating potential as effective anti-cancer agents while maintaining normal cellular functions, and are designed for both mammalian and non-mammalian therapeutic applications.
Implementation Method 1
All act as specific, allosteric inhibitors of Eg5 ATPase activity
Data Source
AI summary
Embodiments of the present invention comprises a compound of formula I or its enantiomer, diastereomer, stereoisomer or its pharmaceutically acceptable salt, methods of use and methods of synthesis.